M e d i a s e t G r o u p
|
|
- Ashley Ball
- 6 years ago
- Views:
Transcription
1 M e d i a s e t G r o u p 11 th May First Quarter Results
2 M e d i a s e t G r o u p BROADCASTING
3 MEDIASET Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0% 44.4% 2.2% 3.7% Stable Growth OTHER TERRESTRIAL 5.8% -0.6 Source: Auditel, Individuals BROADCASTING 3
4 MEDIASET Q Still Leader in Prime Time Individuals Commercial Target (15-64yrs) 45.0% 44.5% 46.6% 42.3% Source: Auditel BROADCASTING 4
5 MEDIASET Q Channel Ranking PRIME TIME Individuals yrs yrs RAI CANALE CANALE CANALE RAI RAI ITALIA ITALIA ITALIA RAI RAI RAI RAI RAI RAI RETE RETE RETE Source: Auditel BROADCASTING 5
6 MEDIASET Q CANALE 5: Audience Share PEAK TIME (21:00 23:00) Share Points Vs 1Q 2003 Share Points Vs 1Q 2003 INDIVIDUALS 24.6% +1,4 24.2% = yrs 25.7% % -0.5 Source: Auditel BROADCASTING 6
7 MEDIASET Q Ad Break Audience Performance PEAK TIME (21:00 23:00) Individuals Commercial Target (15-64yrs) 13.6% 31.7% Source: Auditel BROADCASTING 7
8 MEDIASET Q ITALIA 1: 3rd Channel in Prime Time Individuals 11.2% 9.5% Commercial Target (15-34yrs) 16.1% 8.8% Source: Auditel BROADCASTING 8
9 MEDIASET Q RETE4: Strong Growth PRIME TIME Share Points Vs 1Q 2003 INDIVIDUALS 9.0% +1.1 MALE TARGET 9.5% +1.7 Source: Auditel BROADCASTING 9
10 MEDIASET Q Ad Break Audience Performance 24 HOURS % Vs Estimated Impacts JANUARY FEBRUARY MARCH INDIVIDUALS HOUSEWIVES* +1.1 = yrs +3.0 = +4.9 Source: Auditel * Women over 20 yrs BROADCASTING 10
11 M e d i a s e t G r o u p ADVERTISING 2004 First Quarter Results
12 MEDIASET Q Advertising Revenues ml ADV Revenues +8.1% Vs 1Q Q Q Q ADVERTISING 12
13 MEDIASET Q 4-YEAR Advertising Trend Q Q Q Q Q Source: Infoadex Nielsen Estimates ADVERTISING 13
14 ITALIAN MARKET Q Advertising Trend by Sector 2004 vs 2003 FINANCE/INSURANCE TELECOM AUTOMOTIVE MEDIA & PUBLISHING RETAIL +33.6% +21.3% +12.8% +24.5% +46.2% ADVERTISING 14
15 MEDIASET Q Advertising by Sector 1Q2004 (ml ) 2004 vs vs 2002 FOOD % +2.7% NON FOOD % -7.5% AUTOMOTIVE % +2.0% FINANCE/INSURANCE % -28.7% TELECOM % +8.8% MEDIA & PUBLISHING % +22.4% ADVERTISING 15
16 MEDIASET Q New Clients Acquisition Policy Active Clients New Clients in 1Q New Clients Revenues 12.8 ml ADVERTISING 16
17 M e d i a s e t G r o u p BROADCASTING 2004 First Quarter Results
18 TELE Q TV Audience Share PRIME TIME Individuals Commercial Target 24,1 23,9 26,8 28,3 22,5 22,8 19,0 19,2 18,3 17,8 20,1 18,8 17,0 20,0 18,8 16, Source: Sofres, Prime Time, Individuals (4+ years), Commercial Target (13-54 years) BROADCASTING 18
19 TELE Q TV Audience Share 24 Hours Individuals Commercial Target 23,7 22,9 24,7 25,2 21,4 19,7 18,8 22,1 20,1 17,7 21,0 19,5 16,6 21,4 18,9 15, Source: Sofres, 24 hours, Individuals (4+ years), Commercial Target (13-54 years) BROADCASTING 19
20 M e d i a s e t G r o u p ADVERTISING 2004 First Quarter Results
21 TELECINCO Q Advertising Revenues +21.2% +28.2% ADV Revenues +21.2% Vs 1Q 2003 ( ml) Source: Publiespana ADVERTISING 21
22 M e d i a s e t G r o u p 2004 First Quarter Results
23 MEDIASET GROUP Consolidated Results ( ml.) 1Q Q 2003 Net Consolidated Revenues Operating Costs EBITDA Amortisation & Depreciation EBIT pre Goodwill Amortisation Tele5 Goodwill Amortisation EBIT Pre-Tax Profit (355.9) (209.8) (10.8) (309.1) (248.6) (10.8)
24 ITALIAN BUSINESS 24
25 MEDIASET ITALIAN BUSINESS Financial Results ( ml.) 1Q Q 2003 Net Consolidated Revenues Operating Costs EBITDA Amortisation & Depreciation EBIT Pre-Tax Profit (281.1) (168.4) (243.7) (199.6)
26 MEDIASET ITALIAN BUSINESS Operations Breakdown ( ml.) Total Net Revenues EBIT EBIT margin TV Operations % Non TV Operations % DTT Operations 3.8 (8.8) n.a % 26
27 MEDIASET ITALIAN BUSINESS TV Operations ( ml.) 1Q Q 2003 D % Total Net TV Revenues ,3% TV Advertising Revenues Other TV Revenues Sale of Rights Commissions (111.9) (102.2) Total TV Costs (418.8) (423.9) -1.2% Personnel (76.5) (74.8) TV Operating Costs (180.5) (152.8) TV Amortisations (144.3) (176.2) Other Amortisations & Depreciations (17.5) (20.0) EBIT from TV Operations ,0% margin 35.9% 31.1% 27
28 MEDIASET ITALIAN BUSINESS Non TV Operations ( ml.) 1Q Q 2003 Total Non TV Revenues Thematic Channels Teletext Internet Other Non-TV Revenues Total Non TV Costs Personnel Multimedia Operating Costs Non-TV Operating Costs Amortisations & Depreciations EBIT from Non TV Operations margin (18.0) (2.6) (6.3) (6.1) (3.0) % (19.0) (2.7) (6.2) (6.8) (3.3) % 28
29 MEDIASET ITALIAN BUSINESS DTT Operations ( ml.) 1Q Q 2003 Total DTT Revenues Total DTT Costs Personnel DTT Operating Costs Amortisations & Depreciations (12.7) (1.8) (7.3) (3.6) (0.4) (0.1) (0.3) (0.0) EBIT from DTT Operations (8.8) (0.4) 29
30 MEDIASET ITALIAN BUSINESS Non Operating Items ( ml.) 1Q Q 2003 ALBACOM (19.5% stake) Others Total Associates Net Financial Income/(Charges) Total Extraordinary Items (2.4) (0.1) (2.5) 1.4 (0.3) (10.3) - (10.3) (7.5) (0.1) 30
31 MEDIASET ITALIAN BUSINESS Cash Flow Statement ( ml.) 1Q Q 2003 Net Financial Position 1/1 Free Cash Flow Cash Flow from Operations Investments Disinvestments Change in Net Working Capital Equity (Investments)/Disinvest. Dividends Cashed-in Dividends from Tele5 Total Net Cash Flow Net Financial Position 31/3 (451.4) (136.2) (95.1) (170.8) (133.8) - (53.4) (276.0) - - (74.5) (245.3) 31
32 MEDIASET ITALIAN BUSINESS Investments ml ml Q Q TV Rights Technical & Immaterial DTT investments ( ml.) 32
33 TELECINCO 33
34 TELECINCO Financial Results ( ml.) ITALIAN GAAP 1Q Q 2003 Total Net Revenues Total Costs Personnel Operating Costs Amortisation & Depreciation EBIT Pre-tax Profit (116.4) (16.8) (58.1) (41.5) (114.4) (16.1) (49.3) (49.0)
35 TELECINCO Cash Flow Statement ( ml.) ITALIAN GAAP 1Q Q 2003 Net Financial Position 1/1 Free Cash Flow Cash Flow from Operations Investments Disinvestments Change in Net Working Capital Equity (Investments)/Disinvest. Dividends Total Net Cash Flow Net Financial Position 31/ (58.4) (52.6)
36 MEDIASET GROUP Back up Slides 36
37 MEDIASET GROUP Consolidated Results ( ml.) 1Q 2004 Consolidated 1Q 2004 Mediaset 1Q 2004 Telecinco Consolidation Effects Net Consolidated Revenues (0.1) Operating Costs (355.9) (281.1) (74.9) 0.1 EBITDA Amortisation & Depreciation (209.8) (168.4) (41.5) - EBIT pre Goodwill Amortisation Tele5 Goodwill Amortisation (10.8) - - (10.8) EBIT (10.8) Pre-Tax Profit (10.8) 37
38 MEDIASET GROUP Consolidated Cash Flow ( ml.) 1Q Q 2003 Net Financial Position 1/1 Free Cash Flow Cash Flow from Operations Investments Disinvestments Change in Net Working Capital Change in Consolidation Area Equity (investments)/disinvest. Dividends Total Net Cash Flow Net Financial Position 31/3 (*): including 142.3m. Tele5 1/1/2003 Net Financial Position (199.3) (194.6) (170.8) (186.4) - (27.4) (133.7) * (59.5) 38
39 MEDIASET ITALIAN BUSINESS Back up Slides 39
40 MEDIASET ITALIAN BUSINESS Revenues Breakdown ( ml.) 1Q Q 2003 Total Net TV Revenues TV Advertising Revenues Other TV Revenues Sales of Rights Commissions Total Net Multimedia Revenues Non TV Revenues DTT Revenues Total Net Revenues (111.9) (102.2)
41 MEDIASET ITALIAN BUSINESS Operating Costs Breakdown ( ml.) 1Q Q 2003 Personnel Costs TV Operating Costs Commercial Costs In-house Production Transmission Costs Overheads Multimedia Operating Costs Non TV Operating Costs DTT Operating Costs Total Operating Costs (80.8) (180.5) (20.5) (138.0) (7.0) (15.0) (6.3) (6.1) (7.3) (281.1) (77.6) (152.8) (19.8) (111.0) (7.9) (14.1) (6.2) (6.8) (0.3) (243.7) 41
42 MEDIASET ITALIAN BUSINESS Amortisation & Depreciation -15.6% Depreciation And Other Amortisation ( ml.) ,0 +2.6% TV Rights Amortisation ( ml.) % Q Q
43 TELECINCO Back up Slides 43
44 TELECINCO TV Revenues Breakdown ( ml.) ITALIAN GAAP 1Q Q 2003 Net TV Advertising Revenues Gross TV Advertising Revenues Agency Commissions Other Net Revenues Total Net Revenues (10.9) (11.4)
45 TELECINCO TV Operating Costs Breakdown ( ml.) ITALIAN GAAP 1Q Q 2003 Personnel Costs TV Operating Costs Commercial Costs In-house Production Transmission Costs Overheads Total Operating Costs (16.8) (58.1) (1.1) (42.5) (4.3) (10.2) (74.9) (16.1) (49.3) (1.5) (35.3) (4.5) (8.0) (65.4) 45
46 TELECINCO Amortisation & Depreciation ( ml.) ITALIAN GAAP % ,1 Other Depreciation & Amortisation ( ml.) 3,7-27.5% TV Rights Amortisation & Depreciation ( ml.) 37,8-13.9% 43,9 1Q Q
47 TELECINCO Non Operating Items ( ml.) ITALIAN GAAP 1Q Q 2003 Total Associates 0.1 (0.7) Net Financial Income/(Charges) Total Extraordinary Items (0.2) (0.4) 47
48 TELECINCO Investments 58.4 ml ml Q Q TV Rights Tangible & Intangible Fixed Assets ITALIAN GAAP 48
49 DISCLAIMER Statements contained in this document, particularly the ones regarding any Mediaset Group possible or assumed future performance, are or may be forward looking statements and in this respect they involve some risks and uncertainties. Mediaset Group actual results and developments may differ materially from the ones expressed or implied by the above statements depending on a variety of factors. Any reference to past performance of Mediaset Group shall not be taken as an indication of future performance. The content of this document is not, and shall not be considered as, an offer document or an offer or solicitation to buy or sell any stock. 49
1Q 2009 Results Presentation. 12 May 2009
1Q 2009 Results Presentation 12 May 2009 1 Broadcasting 2 MEDIASET 2009 1Q Total Audience TOTAL AUDIENCE (Jan-Mar) * Individuals Δ vs. 2008 +5.3% 15-64 years +5.6% 1Q TV CONSUMPTION (2000-2009) Average
More information2010 First Quarter Results Presentation. 11 th May 2010
2010 First Quarter Results Presentation 11 th May 2010 1 Broadcasting 2 ITALY TV Consumption trend (2003-2010) Average Daily minutes 271 273 270 270 Individuals 269 266 255 250 251 245 251 256 245 244
More informationMARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationWelcome to LG Electronics
Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.
More information1Q2005. Hera Group presentation
1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationWntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationLeading Intimate Healthcare. Investor presentation Q1 2007/08
Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1
More informationWoongjin Coway. 1Q 12 IR Presentation
Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700
More informationColoplast A/S. Investor Presentation 2005/06
Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &
More informationSummary Statement of Financial Position (consolidated)
2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationPRESENTATION ON 2017 THIRD QUARTERLY RESULTS
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationSecond Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1
Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationVITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar
VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish
More informationValneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017
Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total
More informationPassion for progress, care for people
Passion for progress, care for people SPIL Analyst Meeting 25 th April, 2008 DISCLAIMER ACTUAL RESULTS / OUTCOMES MAY BE DIFFERENT FROM ANY FORWARD LOOKING STATEMENTS / VIEWS / ESTIMATES EXPRESSED HEREIN.
More informationBudimex Group Presentation for investors for 1Q 2008
Budimex Group Presentation for investors for 1Q 2008 Our strategy 40 years on the market Building long term value backlog value significant growth and structure change solid platform for future growth
More informationTotal Face Group Limited
Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position
More information1Q2017 法人說明會 Jun. 9, 2017
1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic
More informationWntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Company announcements +32% +58% Pearls on a string has had troublesome times, but now everything seems to fall into place. With a new CEO in charge the phase II trials close to commencing in
More informationPIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015
PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015 KEY MESSAGES AGENDA 1Q 2015 RESULTS 2015 OUTLOOK & TARGETS 1Q 2015 TYRE OVERVIEW APPENDIX 1Q 2015 RESULTS 1 KEY MESSAGES > A solid 1Q 2015 with Premium outperformance
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationLeading Intimate Healthcare
21 May 2008 1 Leading Intimate Healthcare Investor presentation H1 2007/08 2 Agenda Introduction to Coloplast First 6 months 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationPVD (PVDrilling) Company Visit October 2011
PVD (PVDrilling) Company Visit October 2011 2011 Preview: 3Q11 EBT margin is expected to be higher than 2Q11 largely due to no booking of provision for Science and Technology Development Fund According
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationFinancial Results of the Asseco Group for the 1 st quarter of Warsaw, 14 May 2009
Financial Results of the Asseco Group for the 1 st quarter of 2009 Warsaw, 14 May 2009 Agenda Summary of the 1 st quarter of 2009 Nearest plans 2 Financial highlights Consolidated data Sales* Proprietary
More informationSPY Imaging for Surgeons
SPY Imaging for Surgeons Forward-Looking Statements These slides accompany an oral presentation by Novadaq Technologies, Inc., which contains forwardlooking statements. Actual results may differ materially
More informationQ2 INVESTOR KIT JANUARY-JUNE 2011
Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist
More informationAPPLIANCE TELECOMMUNICATIONS
May 2001 1 DEVICE CRT PDP CRT components APPLIANCE Air Conditioner Refrigerator Washing machine Cooking appliance DISPLAY& MEDIA TV / Monitor CD-ROM DVD products VCR / PC / PCB TELECOMMUNICATIONS Switching
More informationNatus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017
Natus Medical Incorporated Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Forward-Looking Statements This presentation contains forward-looking statements including statements regarding our
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
More informationPresentation First quarter 2006
Immunity for Life TM Presentation First quarter 2006 CEO Gunnar Rørstad CFO Finn Samuelsen 10 May 2006 Highlights - operations Inclusion of patients almost completed in the the phase II clinical trial
More informationImmunity for Life TM. Third Quarter CEO Lars Viksmoen CFO Finn Samuelsen. 31 October 2007
Immunity for Life TM Third Quarter 2007 CEO Lars Viksmoen CFO Finn Samuelsen 31 October 2007 Operational Highlights for Q3 2007 Clinical phase III study with SBG for treatment of diabetic ulcers; enrolment
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationGrowth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor
More informationINVESTOR PRESENTATION SEPTEMBER 2017
INVESTOR PRESENTATION SEPTEMBER 2017 DABUR OVERVIEW One of the oldest and largest FMCG Companies in the country World s largest in Ayurveda and natural healthcare Total reach of 6 mn outlets, one of the
More informationBancAnalysts Association of Boston Conference Presentation. November 3, 2017
BancAnalysts Association of Boston Conference Presentation November 3, 2017 Disclaimer This presentation contains forward- looking statements within the meaning of the Private Securities Litigation Reform
More informationJ.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009
J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK
Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set
More informationJT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007
Contact: Yukiko Seto General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292 FOR IMMEDIATE RELEASE JT Reports Consolidated Financial Results For the Nine-Month Period
More informationSirtex Medical Ltd Buy
Research Sirtex Medical Ltd Buy Price: A$16.32 Price Target: A$20.50 ASX: SRX 21 April 2017 Sirtex Medical (SRX) is a global medical device company which targets cancer therapies, with its lead product
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationResults Briefing Junichi Yoshii President & Representative Director
Fiscal Year Ending March 2010 Results Briefing Junichi Yoshii President & Representative Director May 14, 2010 1 Overview of Results (Consolidated) (Million yen) Net sales Operating profit Recurring income
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationFirst Quarter Results to March 31, Shire plc April 25, 2008
First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationOncosil (OSL) 100% Disease Control Rate. Maintain Buy (Speculative) Rating SOURCE: BELL POTTER SECURITIES ESTIMATES
Analyst John Hester 612 8224 2871 Oncosil (OSL) 23 October 2017 Speculative See key risks on Page 3 and Biotechnology Risk Warning on Page 7. Speculative securities may not be suitable for Retail Clients.
More informationŚCIŚLE POUFNE. The Company's presentation
The Company's presentation Warsaw, May 2017 Key figures #1 Leader of the market of reinforced concrete prefabricated elements in Poland 4 plants manufacturing reinforced concrete prefabricated elements
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
More informationGroup financial results for the first quarter 2008
Helmut Perlet, Member of the Board of Management Group financial results for the first quarter 2008 Journalists Conference Call May 9th, 2008 Group: robust earnings in stormy weather (EUR mn) Quarterly
More informationFY2016 1H Results. Cookpad Inc.
FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising
More informationNASDAQ: FHCO 2016 Annual Meeting
NASDAQ: FHCO 2016 Annual Meeting Q1 2016 At a Glance NASDAQ Core product FHCO FC2 Female Condom Gross margin ~66% Operating margin ~29% Total current assets $24 million no L/T debt Profitable Starting
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More informationNobel Biocare Group Full Year Report 2005
Nobel Biocare Group Full Year Report 2005 Zurich, Switzerland 9 February 2006 Nobel Biocare again outpaces market with record revenue growth of 25% and an EBIT margin of 33.5% in 2005 Revenue for the full
More informationSlide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes
Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationMICROCAP LEADERSHIP SUMMIT
MICROCAP LEADERSHIP SUMMIT WESTIN CHICAGO NORTHWEST HOTEL ITASCA, IL SEPTEMBER 23, 2016 SAFE HARBOR STATEMENT This presentation may be deemed to contain certain forward-looking statements with respect
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationQUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010
QUALITAS MEDICAL GROUP LIMITED CORPORATE PRESENTATION January 2010 Contents Our Business Corporate Developments Growth Strategies Financial Highlights Summary Business Overview Who We Are Established in
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationHemispherx Biopharma AMEX: HEB
Hemispherx Biopharma AMEX: HEB Re-commercialization Proceeds with some delay Hemispherx Biopharma, Inc., a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationMedivir Q Conference call 18 February, 2016
Medivir Q4-2015 Conference call 18 February, 2016 Niklas Prager CEO Ola Burmark CFO Richard Bethell EVP R&D A research-based pharmaceutical company with focus on infectious diseases and oncology Q4 Highlights
More information